Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018

Purpose Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and ov...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2018-11, Vol.172 (2), p.265-272
Main Authors: Barbosa C Rocha, Fernanda, Falcone, Ana Beatriz, Buzaid, Antonio Carlos, Pimenta, Juliana Martins, Schvartsman, Gustavo, Frasson, Antonio Luiz
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Brazil - epidemiology
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - epidemiology
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Breast surgery
Cancer research
Cancer therapies
Chemotherapy
Clinical medicine
Cytotoxicity
Drug therapy
Evidence-based medicine
Female
Health aspects
Humans
Mastectomy
Medical societies
Medicine
Medicine & Public Health
Neoadjuvant Therapy
Oncology
Physicians
Review
Surgeons
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Breast cancer neoadjuvant chemotherapy (NAC) consists of the administration of cytotoxic and targeted drugs prior to breast surgery, with the objective of reducing the tumor burden to allow breast conservation. NAC also aims to improve long-term treatment outcomes such as disease-free and overall survival. To optimize clinical practice with the best available evidence for breast cancer patients in the setting of neoadjuvant treatment, the Brazilian Society of Breast Surgeons (Sociedade Brasileira de Mastologia—SBM) held a consensus conference to develop this guideline. Methods Twenty-two questions addressing relevant breast cancer neoadjuvant treatment were previously formulated. The voting panel comprised 25 specialists from the SBM. A consensus was established if there was 75% agreement. If there was less concordance, after discussion, the consensus was determined by a 51% concordance. Results The recommendations were based on the best level of scientific evidence and the opinion from breast cancer experts, when no such research data were available. Conclusion This manuscript provides updated guidance according to the views of the SBM’s experts for the clinical practice of breast cancer surgeons. This manuscript depicts the summarized recommendations for NAC treatment.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-018-4912-x